146 related articles for article (PubMed ID: 30247103)
1. Effect of Standardized Infliximab Dose Rounding on an Outpatient Infusion Center.
Park JJ; Boutillier L; Cruz JE; Joung G; Nemeth J
J Manag Care Spec Pharm; 2018 Oct; 24(10):1028-1033. PubMed ID: 30247103
[TBL] [Abstract][Full Text] [Related]
2. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.
Vande Casteele N; Ferrante M; Van Assche G; Ballet V; Compernolle G; Van Steen K; Simoens S; Rutgeerts P; Gils A; Vermeire S
Gastroenterology; 2015 Jun; 148(7):1320-9.e3. PubMed ID: 25724455
[TBL] [Abstract][Full Text] [Related]
3. Need for infliximab dose intensification in Crohn's disease and ulcerative colitis.
Taxonera C; Olivares D; Mendoza JL; Díaz-Rubio M; Rey E
World J Gastroenterol; 2014 Jul; 20(27):9170-7. PubMed ID: 25083091
[TBL] [Abstract][Full Text] [Related]
4. Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb.
Bhat S; Altajar S; Shankar D; Zahorian T; Robert R; Qazi T; Shah B; Farraye FA
J Manag Care Spec Pharm; 2020 Apr; 26(4):410-416. PubMed ID: 32223602
[TBL] [Abstract][Full Text] [Related]
5. Short article: Remicade infusions at home: an alternative setting of infliximab therapy for patients with Crohn's disease.
Kuin S; Stolte SB; van den Brink GR; Ponsioen CY; Fockens P; D'Haens GR; Löwenberg M
Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):222-5. PubMed ID: 26566062
[TBL] [Abstract][Full Text] [Related]
6. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
[TBL] [Abstract][Full Text] [Related]
7. Implementation of infliximab standardized doses after pharmacokinetic modelization in a cohort of patients with Crohn's disease.
Poullenot F; Ollivier J; Rivière P; Sauvaget L; Berroneau A; Djabarouti S; Xuereb F; Zerbib F; Breilh D; Laharie D
Dig Liver Dis; 2020 Apr; 52(4):408-413. PubMed ID: 31874834
[TBL] [Abstract][Full Text] [Related]
8. Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.
Giese-Kim N; Wu M; Dehghan M; Sceats LA; Park KT
Am J Gastroenterol; 2020 Oct; 115(10):1698-1706. PubMed ID: 32701731
[TBL] [Abstract][Full Text] [Related]
9. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting.
Ollendorf DA; Lidsky L
Am J Ther; 2006; 13(6):502-6. PubMed ID: 17122530
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of infliximab in Crohn's disease.
Smart C; Selinger CP
Expert Rev Pharmacoecon Outcomes Res; 2014 Oct; 14(5):589-98. PubMed ID: 25138162
[TBL] [Abstract][Full Text] [Related]
11. Non-drug costs associated with outpatient infliximab administration in pediatric inflammatory bowel disease.
Wu M; Sin A; Nishioka F; Park KT
Inflamm Bowel Dis; 2013 Jun; 19(7):1514-7. PubMed ID: 23567783
[TBL] [Abstract][Full Text] [Related]
12. Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting.
Checkley LA; Kristofek L; Kile S; Bolgar W
Dig Dis Sci; 2019 Mar; 64(3):855-862. PubMed ID: 30311152
[TBL] [Abstract][Full Text] [Related]
13. Healthcare resource utilization and treatment costs of Finnish chronic inflammatory bowel disease patients treated with infliximab
Ylisaukko-Oja T; Torvinen S; Ventola H; Schmidt S; Herrala S; Kononoff J; Voutilainen M
Scand J Gastroenterol; 2019 Jun; 54(6):726-732. PubMed ID: 31203693
[No Abstract] [Full Text] [Related]
14. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia.
AlRuthia Y; Almadi M; Aljebreen A; Azzam N; Alsharif W; Alrasheed H; Almuaythir G; Saeed M; HajkhderMullaissa B; Alharbi O
J Med Econ; 2020 Oct; 23(10):1102-1110. PubMed ID: 32619388
[TBL] [Abstract][Full Text] [Related]
15. Health care resource use and costs in Crohn's disease before and after infliximab therapy.
Loomes DE; Teshima C; Jacobs P; Fedorak RN
Can J Gastroenterol; 2011 Sep; 25(9):497-502. PubMed ID: 21912761
[TBL] [Abstract][Full Text] [Related]
16. Dose Escalation Assessment Among Targeted Immunomodulators in the Management of Inflammatory Bowel Disease.
Ehrenberg R; Griffith J; Theigs C; McDonald B
J Manag Care Spec Pharm; 2020 Jun; 26(6):758-765. PubMed ID: 32191593
[TBL] [Abstract][Full Text] [Related]
17. Systematic analysis of annual health resource utilization and costs in hospitalized patients with inflammatory bowel disease in Switzerland.
Schoepfer A; Vavricka SR; Brüngger B; Reich O; Blozik E; Bähler C
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):868-875. PubMed ID: 29757772
[TBL] [Abstract][Full Text] [Related]
18. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
[TBL] [Abstract][Full Text] [Related]
19. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease.
Binkhorst L; Sobels A; Stuyt R; Westerman EM; West RL
Eur J Gastroenterol Hepatol; 2018 Jul; 30(7):699-703. PubMed ID: 29538037
[TBL] [Abstract][Full Text] [Related]
20. Costs of providing infusion therapy for patients with inflammatory bowel disease in a hospital-based infusion center setting.
Afzali A; Ogden K; Friedman ML; Chao J; Wang A
J Med Econ; 2017 Apr; 20(4):409-422. PubMed ID: 28112566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
